The research team, led by Le Song and Na Guo, with Weifang Zhang as corresponding author, combed through bone scintigraphy studies performed at their institution between 2019 and 2022. Among thousands of scans, they identified 66 patients who displayed focal uptake within the orbital region, an incidence of roughly 0.9 percent of all bone scans. That figure alone is informative: orbital uptake is uncommon, which is precisely why most physicians have lacked the large, longitudinally followed cohorts needed to say anything confident about it. By assembling 66 patients and evaluating 76 distinct orbital foci, the Beijing group created one of the first multi-modality portraits of this finding, combining planar bone scintigraphy with magnetic resonance imaging, computed tomography, fluorine-18 fluorodeoxyglucose positron emission tomography, and, crucially, follow-up imaging over many months.

The anatomical and morphological patterns that emerged were strikingly consistent. Of the 76 orbital foci, 61, or 80.3 percent, localized to the superior or lateral walls of the orbit, and 72, or 94.7 percent, appeared round in shape. Those two features, a predilection for the upper and outer orbital walls and a rounded contour, are exactly what one would expect from slow-growing, indolent processes such as fibrous dysplasia or other benign osseous variants, and exactly what one would not expect from the ragged, permeative architecture of metastatic deposits. Meanwhile, the extra-orbital findings in these patients told a separate story about why the scans had been ordered in the first place: five patients had bona fide skeletal metastases elsewhere, 34 showed degenerative changes, and 17 harbored other benign lesions.

The technical heart of the study lies in its quantitative analysis of the target-to-nontarget ratio, a standard measure in bone scintigraphy that compares tracer intensity in a suspicious focus with that in adjacent normal bone. In the 27 patients who underwent follow-up bone scintigraphy, at a median interval of 23.0 months, the median T/NT ratio drifted from 4.9 down to 3.7, a change that did not reach statistical significance, with a P value of 0.301. More telling than the ratio itself was the visual verdict: 25 of 28 lesions examined longitudinally appeared unchanged on side-by-side comparison, and that stability held equally among patients with known metastatic disease, four of five lesions, and patients without metastases, 21 of 23 lesions. Metastatic lesions in bone, by contrast, typically evolve, intensifying as disease progresses or fading in response to therapy, particularly during the flare phenomenon that follows effective treatment.

Magnetic resonance imaging provided a second, complementary line of evidence. Within 14 days of their bone scans, 31 patients underwent orbital MRI, which detected abnormal orbital lesions in 16 patients, corresponding to 16 lesions with a mean size of 9.0 plus or minus 2.4 millimeters. The frontal bone was involved in ten cases and the zygomatic bone in six, once again mirroring the superior and lateral orbital walls highlighted on scintigraphy. When the researchers applied the Bone Reporting and Data System, a structured classification scheme designed to standardize the risk assessment of bone lesions, 12 of these lesions fell into the low-concern category 2 or 3, while four were assigned to the more worrisome category 4. Follow-up MRI in 11 lesions showed no change in size over time, although two lesions did display evolution in their signal characteristics, a reminder that even ostensibly benign orbital lesions deserve at least individualized attention rather than reflexive dismissal.

It was computed tomography, however, that emerged as the decisive diagnostic tool. In 21 patients who underwent CT or fluorine-18 FDG PET/CT at a median interval of eight months from the index bone scan, CT identified abnormal orbital findings in 20 patients, totaling 21 foci. Nineteen of those 21 foci, all but one, displayed unambiguously benign features. Eighteen were classified as Bone-RADS category 1, and 16 of these showed the classic ground-glass opacity, a hazy, milky pattern of mineralization that radiologists regard as a near-signature of fibrous dysplasia, a developmental benign bone lesion in which normal marrow is replaced by a fibrous tissue woven with immature trabeculae. Two further foci were lucent lesions of Bone-RADS category 2 or 3. The single exception was an osteolytic lesion of the sphenoid bone exhibiting cortical destruction, assigned Bone-RADS category 4, with an SUVmax of 5.1 on PET, findings that were interpreted as suggestive of metastasis. That outlier is clinically important: it demonstrates that while the pattern is overwhelmingly benign, the occasional genuine metastasis does hide among these hot spots, and imaging characterization, not assumption, is what separates the two.

The metabolic dimension of the study adds a third layer of reassurance. On fluorine-18 FDG PET/CT, the 20 benign-appearing foci showed minimal fluorodeoxyglucose uptake, with a median maximum standardized uptake value of just 1.4. FDG avidity reflects glucose metabolism, and actively proliferating tumor tissue typically consumes the tracer eagerly, driving SUV values well above the benign threshold. A median SUVmax of 1.4 places these orbital lesions firmly in the metabolically quiet company of normal tissue, consistent with the slow, remodeled bone of fibrous dysplasia rather than the voracious biochemistry of metastatic carcinoma. Taken together, the low metabolic activity, the rounded morphology, the characteristic ground-glass attenuation on CT, and the longitudinal stability across a median follow-up approaching two years form a converging constellation of benignity that is difficult to argue with.

Why does this matter beyond the reading room? Incidental findings have become one of the defining challenges of modern imaging. As scanners grow more sensitive and whole-body protocols more common, radiologists increasingly detect anomalies whose clinical significance is unknown, and each of them triggers a cascade of anxiety, additional testing, cost, and sometimes unnecessary invasive procedures for patients already frightened by cancer diagnoses. Bone scintigraphy is performed millions of times a year worldwide, and if roughly one percent of those scans carry an orbital hot spot, the aggregate burden of uncertainty is substantial. By demonstrating that these foci have a reproducible benign signature, the study converts a source of ambiguity into a pattern that can be recognized, characterized, and, in most cases, safely managed without biopsy or aggressive intervention.

The study also carries a practical methodological lesson about the relative strengths of different imaging modalities. MRI, so exquisitely sensitive to marrow infiltration and soft tissue, proved less definitive for these osseous lesions, and its signal characteristics could even evolve over time in ways that complicate interpretation. CT, by contrast, excelled at characterizing the internal architecture of the bone itself, reliably distinguishing the ground-glass mineralization of fibrous dysplasia from the cortical destruction of malignancy. Combined with the metabolic information from FDG PET, CT offered superior osseous characterization versus MRI in this cohort, a conclusion the authors state explicitly and one that should guide clinicians choosing the most efficient follow-up test for an incidental orbital hot spot.

The Beijing team is careful not to advocate for total neglect. Their conclusion endorses individualized imaging surveillance, an approach tailored to each patient’s cancer history, lesion characteristics, and risk profile, rather than a blanket policy of either reflexive biopsy or reflexive dismissal. The five patients with metastatic disease and the single sphenoid metastasis with cortical destruction underscore that context matters: in a patient with widespread progressive malignancy, an orbital focus demands closer scrutiny than the same focus in a patient with degenerative disease and stable imaging elsewhere. But the central message of the study is clear and, for thousands of future patients, genuinely comforting. The small round light beside the eye on a bone scan is, in the vast majority of cases, not a spreading cancer but a quiet quirk of bone biology, a lesion that has likely sat there harmlessly for years and will still be sitting there, unchanged, years from now. In the high-stakes world of oncological imaging, that kind of evidence-based reassurance is worth its weight in technetium.

Subject of Research: Incidental orbital radionuclide uptake on bone scintigraphy and its benign etiology

Article Title: Benign nature of incidental orbital uptake on bone scintigraphy: insights from multi-modality imaging and follow-up

Article References: Song, L., Guo, N., & Zhang, W. (2026). Benign nature of incidental orbital uptake on bone scintigraphy: insights from multi-modality imaging and follow-up. BMC Medical Imaging. https://doi.org/10.1186/s12880-026-02844-9

Image Credits: AI Generated

DOI: 10.1186/s12880-026-02844-9

Keywords: bone scintigraphy, orbital lesions, incidental findings, fibrous dysplasia, Bone-RADS, FDG PET/CT, MRI, SUVmax, metastasis, nuclear medicine, multimodal imaging, ground-glass opacity